Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Gil-Chun | - |
dc.contributor.author | Hwang, Shin | - |
dc.contributor.author | Kim, Myoung-Soo | - |
dc.contributor.author | Jung, Dong-Hwan | - |
dc.contributor.author | Song, Gi-Won | - |
dc.contributor.author | Lee, Kwang-Woong | - |
dc.contributor.author | Kim, Jong Man | - |
dc.contributor.author | Lee, Jae Geun | - |
dc.contributor.author | Ryu, Je Ho | - |
dc.contributor.author | Choi, Dong Lak | - |
dc.contributor.author | Wang, Hee-Jung | - |
dc.contributor.author | Kim, Bong-Wan | - |
dc.contributor.author | Kim, Dong-Sik | - |
dc.contributor.author | Nah, Yang Won | - |
dc.contributor.author | You, Young Kyoung | - |
dc.contributor.author | Kang, Koo Jeong | - |
dc.contributor.author | Yu, Hee Chul | - |
dc.contributor.author | Park, Yo-Han | - |
dc.contributor.author | Lee, Kyung Jin | - |
dc.contributor.author | Kim, Yun Kyu | - |
dc.date.accessioned | 2021-08-31T10:11:42Z | - |
dc.date.available | 2021-08-31T10:11:42Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-02-17 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/57637 | - |
dc.description.abstract | Background: Prophylaxis for hepatitis B virus (HBV) recurrence is essential after liver transplantation (LT) in HBV-associated recipients. We conducted real-world analysis of HBV prophylaxis after LT in the Korean population. Methods: Korean Organ Transplantation Registry (KOTRY) database and additionally collected data (n = 326) were analyzed with special reference to types of HBV prophylaxis. Results: The study cohort comprised 267 cases of living-donor LT and 59 cases of deceased-donor LT. Hepatocellular carcinoma (HCC) was diagnosed in 232 (71.2%) of these subjects. Antiviral agents were used in 255 patients (78.2%) prior to LT. HBV DNA was undetectable in 69 cases (21.2%) and detectable over wide concentrations in the other 257 patients (78.8%) prior to LT. Polymerase chain reaction analysis of the store blood samples detected HBV DNA in all patients, with 159 patients (48.9%) showing concentrations > 100 IU/mL. Post-transplant HBV regimens during the first year included combination therapy in 196 (60.1%), hepatitis B immunoglobulin (HBIG) monotherapy in 121 (37.1%), and antiviral monotherapy in 9 (2.8%). In the second post-transplant year, these regimens had changed to combination therapy in 187 (57.4%), HBIG monotherapy in 112 (34.4%), and antiviral monotherapy in 27 (8.3%). Trough antibody to hepatitis B surface antigen titers > 500 IU/mL and >1,000 IU/mL were observed in 61.7% and 25.2%, respectively. The mean simulative half-life of HBIG was 21.6 +/- 4.3 days with a median 17.7 days. Up to 2-year follow-up period, HCC recurrence and HBV recurrence developed in 18 (5.5%) and 6 (1.8%), respectively. HCC recurrence developed in 3 of 6 patients with HBV recurrence. Conclusion: Combination therapy is the mainstay of HBV prophylaxis protocols in a majority of Korean LT centers, but HBIG was often administered excessively. Individualized optimization of HBIG treatments using SHL is necessary to adjust the HBIG infusion interval. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.subject | IMMUNOGLOBULIN MONOTHERAPY | - |
dc.subject | IMMUNE GLOBULIN | - |
dc.subject | VIRUS | - |
dc.subject | MANAGEMENT | - |
dc.subject | RECURRENCE | - |
dc.subject | RECIPIENTS | - |
dc.title | Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Sik | - |
dc.identifier.doi | 10.3346/jkms.2020.35.e36 | - |
dc.identifier.wosid | 000514815500001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.35, no.6 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 35 | - |
dc.citation.number | 6 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002557615 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | IMMUNOGLOBULIN MONOTHERAPY | - |
dc.subject.keywordPlus | IMMUNE GLOBULIN | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.subject.keywordPlus | RECIPIENTS | - |
dc.subject.keywordAuthor | Hepatitis B Virus | - |
dc.subject.keywordAuthor | Recurrence | - |
dc.subject.keywordAuthor | Liver Transplantation | - |
dc.subject.keywordAuthor | Hepatitis B Immunoglobulin | - |
dc.subject.keywordAuthor | Antiviral Agent | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.